Dennis Slamon
American physician / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Dennis Slamon?
Summarize this article for a 10 year old
Dennis Joseph Slamon (born August 6, 1948),[1][2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.[3]
Dennis J. Slamon | |
---|---|
Born | (1948-08-06) August 6, 1948 (age 76) |
Alma mater | Washington & Jefferson College (B.A.) University of Chicago (Ph.D. cell biology, M.D. (1975)) |
Occupation(s) | oncologist, professor |
Awards | Gairdner Foundation International Award (2007) Scheele Award (2009) The Sjöberg Prize (2019) |
He currently serves as director of Clinical/Translational Research at UCLA's Jonsson Comprehensive Cancer Center,[4] and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer.